Synapsin Ii Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Synapsin II (Synapsin-2)</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Synapsin II (Synapsin-2)</td></tr>
<tr><td><strong>Gene</strong></td><td>[SYN2](/genes/syn2)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9T8F2](https://www.uniprot.org/uniprot/Q9T8F2)</td></tr>
<tr><td><strong>Protein Length</strong></td><td>706 amino acids (human isoform a)</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~74 kDa</td></tr>
<tr><td><strong>Subcellular Location</strong></td><td>Synaptic vesicles (presynaptic terminal)</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Synapsin family</td></tr>
</table>
</div>
Synapsin Ii Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Synapsin II (Synapsin-2)</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Synapsin II (Synapsin-2)</td></tr>
<tr><td><strong>Gene</strong></td><td>[SYN2](/genes/syn2)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9T8F2](https://www.uniprot.org/uniprot/Q9T8F2)</td></tr>
<tr><td><strong>Protein Length</strong></td><td>706 amino acids (human isoform a)</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>~74 kDa</td></tr>
<tr><td><strong>Subcellular Location</strong></td><td>Synaptic vesicles (presynaptic terminal)</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Synapsin family</td></tr>
</table>
</div>
Synapsin II (SYN2) is a neuronal phosphoprotein associated with synaptic vesicles in presynaptic terminals. Together with Synapsin I, Synapsin II regulates synaptic vesicle clustering, availability, and neurotransmitter release at synapses. Synapsin II plays essential roles in synaptogenesis, synaptic plasticity, and maintaining synaptic vesicle pools. It is specifically expressed in [neurons](/entities/neurons) and is one of the most abundant synaptic proteins in the mammalian brain. Mutations and dysregulation of SYN2 have been implicated in epilepsy, Alzheimer's disease, Parkinson's disease, and various neuropsychiatric disorders. Synapsin II is a key marker of synaptic integrity and is widely used in neuroscience research as a presynaptic marker.
Synapsin II has a multi-domain structure that mediates its interactions with synaptic vesicles and regulatory proteins. The N-terminal region contains a short domain (domain A) that interacts with the phospholipid membrane of synaptic vesicles in a phosphorylation-dependent manner. This is followed by a linker region and a larger C-terminal domain (domains C-E) that mediates protein-protein interactions. The C-terminal region contains the ATP-binding domain and is involved in homodimerization and interaction with other synapsin family members. Synapsin II shares structural homology with Synapsin I but has distinct phosphorylation sites and binding properties. The protein has multiple isoforms generated by alternative splicing, including Synapsin IIa (full-length) and Synapsin IIb (shorter isoform lacking the N-terminal domain). Phosphorylation by various kinases (PKA, CaMKII, MAP kinases) regulates Synapsin II's association with synaptic vesicles.
In the presynaptic terminal, Synapsin II performs several critical functions. First, it tethers synaptic vesicles to the actin cytoskeleton, forming a reserve pool of vesicles that can be mobilized during sustained neuronal activity. Second, it regulates the number of synaptic vesicles available for release by controlling vesicle clustering and mobilization. Third, it participates in the organization of the active zone and the coordination of vesicle trafficking. During development, Synapsin II is involved in synapse formation and neuronal polarization. The protein is highly enriched in excitatory (glutamatergic) synapses but is also present in inhibitory (GABAergic) synapses. Synapsin II knockout mice exhibit reduced synaptic vesicle pools, impaired synaptic transmission during high-frequency stimulation, and behavioral deficits including seizures and anxiety-like behaviors. The protein interacts with various synaptic proteins including synaptophysin, synaptotagmin, and RIM proteins.
In Alzheimer's disease (AD), Synapsin II levels are significantly reduced in affected brain regions, reflecting synaptic loss, a hallmark of AD pathology. Studies have shown that Synapsin II immunoreactivity decreases in the [hippocampus](/brain-regions/hippocampus) and [cortex](/brain-regions/cortex) of AD patients, correlating with cognitive decline. This reduction reflects the loss of presynaptic terminals rather than a specific effect on Synapsin II expression. Additionally, [amyloid-beta](/proteins/amyloid-beta) (Aβ) pathology can affect Synapsin II indirectly through disruption of synaptic function. Some studies suggest that Synapsin II may interact with [amyloid precursor protein](/entities/app-protein) (APP) processing, potentially influencing amyloidogenesis. As a synaptic marker, Synapsin II is used in research to quantify synaptic density in AD models and to assess the efficacy of potential therapeutic interventions.
Synapsin II dysregulation has been documented in Parkinson's disease (PD) and may contribute to synaptic dysfunction in dopaminergic neurons. Studies on postmortem PD brain have shown altered Synapsin II expression in the substantia nigra and striatum, regions affected in PD. [Alpha-synuclein](/proteins/alpha-synuclein) (α-syn) pathology, a hallmark of PD, can affect synaptic vesicle trafficking and may interact with Synapsin II function. In PD models, Synapsin II expression is reduced in response to mitochondrial toxins and oxidative stress, reflecting synaptic vulnerability. The loss of Synapsin II may contribute to impaired neurotransmitter release and synaptic dysfunction in PD. Additionally, Synapsin II may be involved in the regulation of dopaminergic vesicle pools and tyrosine hydroxylase (TH) activity.
Synapsin II mutations have been linked to epilepsy in humans and animal models. Synapsin II knockout mice exhibit spontaneous seizures and increased susceptibility to experimentally induced seizures. The mechanism involves impaired synaptic vesicle dynamics and altered neurotransmitter release. Studies have identified pathogenic SYN2 variants in patients with epilepsy, supporting a direct role in seizure susceptibility. Synapsin II deficiency leads to depletion of synaptic vesicle reserves and impaired synaptic plasticity, which may contribute to hyperexcitability. These findings have made Synapsin II a target of interest in epilepsy research.
Synapsin II dysregulation has been implicated in various other neurological conditions. In schizophrenia, altered SYN2 expression and genetic associations have been reported, suggesting a role in synaptic dysfunction underlying psychiatric disorders. In Huntington's disease, Synapsin II levels are reduced in affected brain regions, contributing to synaptic dysfunction. In traumatic brain injury, Synapsin II is used as a biomarker of synaptic damage. Additionally, Synapsin II autoantibodies have been detected in some patients with autoimmune encephalitis.
Synapsin II represents a potential therapeutic target for neurodegenerative and neurological disorders:
Key areas of ongoing research include:
The study of Synapsin Ii Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
<sup>[1]</sup> Cesca F, et al. (2010). The synapsins: Key actors of synapse function and plasticity. Progress in Neurobiology 91(4):313-348. PMID: 20470010(https://pubmed.ncbi.nlm.nih.gov/20470010/)
<sup>[2]</sup> Gitler D, et al. (2004). Synapsin IIb is a functional splice variant. Brain Research 1001(1-2):45-52. PMID: 15005168(https://pubmed.ncbi.nlm.nih.gov/15005168/)
<sup>[3]</sup> Feng J, et al. (2002). Synapsin II and the pathogenesis of epilepsy. Trends in Neurosciences 25(8):393-398. PMID: 12127762(https://pubmed.ncbi.nlm.nih.gov/12127762/)
<sup>[4]</sup> Porton B, et al. (2010). Synapsin III: A developmental critical player in brain function? Journal of Neuroscience 30(1):3-10. PMID: 20053884(https://pubmed.ncbi.nlm.nih.gov/20053884/)
<sup>[5]</sup> Forgione N, et al. (2019). Synaptic dysfunction in neurodegenerative diseases: The role of synapsins. Frontiers in Cellular Neuroscience 13:535. PMID: 31920533(https://pubmed.ncbi.nlm.nih.gov/31920533/)
<sup>[6]</sup> Halt AR, et al. (2015). Synapsin regulates vesicle pooling and is required for synaptic plasticity. Nature Communications 6:7512. PMID: 26059513(https://pubmed.ncbi.nlm.nih.gov/26059513/)
The following diagram shows the key molecular relationships involving Synapsin II Protein discovered through SciDEX knowledge graph analysis: